Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

522
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
522
Cross-reactivity00:42

Cross-reactivity

31.5K
Overview
31.5K
Vaccinations01:51

Vaccinations

45.4K
Overview
45.4K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

382
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
382

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transgene Expression Kinetics and Replication Potential of Recombinant Adenovirus Serotype 4 in a Mouse Model and its Use as a Herpes Simplex Virus Vaccine.

bioRxiv : the preprint server for biology·2026
Same author

Immunization with Herpes Simplex Virus Nanoparticles Targeting Both Attachment and Fusion Protect Against Infection.

bioRxiv : the preprint server for biology·2026
Same author

Intranasal Replicating Adenovirus type 4-SARS-CoV-2 Recombinants Induce Superior Immune Response Durability and Efficacy in Preclinical Testing Compared to Standard Intramuscular Vaccines.

bioRxiv : the preprint server for biology·2026
Same author

Intranasal replicating adenovirus type 4-vectored SARS-CoV-2 vaccines induce durable and efficacious responses in preclinical testing.

iScience·2026
Same author

Enhancing, controlling, and sterilizing dengue immunity and the development of broadly protective responses.

medRxiv : the preprint server for health sciences·2026
Same author

Targeted deep sequencing identifies mosaicism in patients with immune dysregulation.

The Journal of allergy and clinical immunology·2026

Related Experiment Video

Updated: Sep 19, 2025

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.3K

Prophylactic and Therapeutic EBV Vaccination.

Rajiv Khanna1, Jeffrey I Cohen2

  • 1QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Current Topics in Microbiology and Immunology
|June 6, 2025
PubMed
Summary

Epstein-Barr virus (EBV) vaccines offer dual benefits: prophylactic vaccines prevent EBV infections and associated diseases, while therapeutic vaccines target existing conditions. Both approaches aim to control EBV

Keywords:
AntibodyBurkitt lymphomaGastric carcinomaHodgkin diseaseInfectious mononucleosisMultiple sclerosisNasopharyngeal carcinomaT cellsVaccine

More Related Videos

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line
09:14

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Published on: September 28, 2022

4.1K
Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

16.0K

Related Experiment Videos

Last Updated: Sep 19, 2025

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.3K
Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line
09:14

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Published on: September 28, 2022

4.1K
Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

16.0K

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Epstein-Barr virus (EBV) is linked to various diseases, including infectious mononucleosis, lymphomas, and autoimmune disorders like multiple sclerosis.
  • EBV's role as a cofactor in certain cancers necessitates targeted interventions.

Purpose of the Study:

  • To explore the potential of Epstein-Barr virus (EBV) vaccines for both preventing primary infection and treating EBV-associated conditions.
  • To differentiate between prophylactic and therapeutic vaccine strategies for EBV.

Main Methods:

  • The study discusses the general principles and targets for developing EBV vaccines.
  • Distinguishes between antibody induction for prophylaxis and T-cell activation for therapeutic applications.

Main Results:

  • Prophylactic EBV vaccines aim to prevent initial infection and associated illnesses such as mononucleosis and posttransplant lymphoproliferative disease.
  • Therapeutic EBV vaccines are designed to treat existing autoimmune diseases and EBV-driven malignancies.

Conclusions:

  • EBV vaccines hold promise for preventing a range of EBV-related diseases and treating established conditions.
  • Tailoring vaccine strategies—prophylactic (antibody-focused) versus therapeutic (T-cell focused)—is key to effectively combating EBV's impact.